Skip to content
Bexagliflozin
Brenzavvy (bexagliflozin) is a small molecule pharmaceutical. Bexagliflozin was first approved as Brenzavvy on 2023-01-20.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Brenzavvy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bexagliflozin
Tradename
Company
Number
Date
Products
BRENZAVVYTheracosbioN-214373 RX2023-01-20
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
brenzavvyNew Drug Application2023-05-12
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
BEXAGLIFLOZIN, BRENZAVVY, THERACOSBIO
2028-01-20NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Bexagliflozin, Brenzavvy, Theracosbio
89873232032-05-14DS, DP
105330322031-07-03U-2214
109819422031-06-13DS, DP
78384992029-01-30DS, DPU-2214
81060212028-08-22U-2214
88026372028-08-22DS, DPU-2214
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11826——16
Essential hypertensionD000075222I10—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBEXAGLIFLOZIN
INNbexagliflozin
Description
Bexagliflozin, sold under the brand name Brenzavvy, is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID1118567-05-7
RxCUI—
ChEMBL IDCHEMBL1808388
ChEBI ID—
PubChem CID25195624
DrugBankDB12236
UNII IDEY00JF42FV (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 48 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details